NCT01407380View on ClinicalTrials.gov

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions
Malignancies
Interventions
DRUG

PWT33597 mesylate

PWT33597 taken orally daily for 28 consecutive days in 28 day cycle

Trial Locations (4)

37203

Sarah Cannon Research Institute, Nashville

85258

Pinnacle Hematology Oncology, Scottsdale

85719

The University of Arizona Cancer Center, Tucson

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Pathway Therapeutics, Inc.

INDUSTRY

NCT01407380 - Study of PWT33597 Mesylate in Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter